NOMINATION: Nanoscope Therapeutics appoints Troy Short SVP, Manufacturing and Supply Chain
Nanoscope Therapeutics, a biotechnology company developing therapies for retinal degenerative diseases, announced on October 14, 2026 that Troy Short had been appointed Senior Vice President, Manufacturing and Supply Chain. The role covers GMP manufacturing, commercial supply and global distribution strategy as Nanoscope advances MOGENRY (MCO-010), an investigational gene therapy, through regulatory review and toward potential commercialization.
According to the official release, Short has more than two decades of pharmaceutical and gene therapy operations and supply chain experience. At AveXis he served as Vice President of Global Supply Chain, helping build supply capabilities for the launch of Zolgensma, including specialized distribution requirements. He subsequently served as Senior Vice President of Manufacturing and Supply Chain at Jaguar Gene Therapy and Chief Operating Officer of Advanced Medicine Partners. His recent consulting work has focused on CMC, supply chain and regulatory submission readiness.
The company describes preparation for manufacturing scale-up, partnerships, quality-dependent supply and distribution ahead of any potential launch. The announcement is a leadership appointment, not evidence that MOGENRY has received regulatory approval or achieved commercial manufacturing volumes. It does not announce an AI programme or quantify operational outcomes.
Official release: https://nanostherapeutics.com/2026/10/14/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain/
Nanoscope's appointment makes manufacturing and supply chain leadership a strategic scaling role before commercial volume exists. The relevant operating-model decision is whether a single accountable executive can connect process development, CMC and quality requirements, manufacturing partnerships and supply readiness as a clinical-stage biotech approaches potential commercialization.
For biopharmaceutical operations leaders, value depends on clear decision ownership across technical development, GMP execution, external manufacturing and distribution readiness. The principal risk is fragmented accountability that leaves the company technically or logistically unprepared for a potential launch despite progress in the regulatory process. The appointment signals intent to strengthen execution capability, not proof of regulatory approval, operational readiness or future commercial success.